Enabling Evolutionary Therapy in metastatic cancer lacking serum biomarkers

Clicks: 14
ID: 328066
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #44 of 74 articles by views in journal of evolutionary biology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Evolutionary therapy (ET) aims to anticipate and steer tumor evolution by adjusting treatment timing and dosing, often to control rather than eradicate tumor burden. Clinical use requires reliable monitoring of tumor dynamics to inform mathematical models that guide therapy. In cancers such as metastatic castrate-resistant prostate cancer and relapsed platinum-sensitive ovarian cancer, ET models are informed by serial serum biomarkers. For cancers lacking reliable biomarkers, such as metastatic non-small cell lung cancer (NSCLC), radiographic imaging remains the primary method for treatment response assessment, typically using RECIST 1.1 criteria. RECIST, which tracks a limited number (up to five) of lesions with one-dimensional (1D) measurements and defines progression relative to the nadir, the smallest tumor burden recorded after treatment, was not designed to support ET. It may miss early regrowth, underrepresent tumor burden, and obscure disease trends. Using a virtual NSCLC patient model, we demonstrate that lesion selection and measurement dimensionality strongly affect progression detection. Two-dimensional metrics provide modest improvement, but only 3D volumetric measurements accurately capture both tumor burden and its dynamics, which are key requirements for ET. To support ET in cancers lacking biomarkers, response assessment must evolve beyond RECIST by integrating volumetric imaging, automated segmentation, and potentially liquid biopsies, alongside redefining progression criteria to enable adaptive, patient-centered treatments.
Reference Key
openalex_W7117116386 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eva Molnárová, Ties A. Mulders, Marcela Spee-Dropková, Louise Spekking, Sepinoud Azimi, I Grossmann, Anne-Marie C Dingemans, Kateřina Staňková
Journal journal of evolutionary biology
Year 2026
DOI
10.1093/jeb/voag070
URL
https://doi.org/10.1093/jeb/voag070
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.